The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.
Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...
Billionaire entrepreneur and top adviser to President-elect Donald Trump, Elon Musk, touted that he has reaped the benefits of a controversial class of weight-loss drugs, after fellow top Trump ...